Evidence map›Paper›PMID 37180332›Full record

ArticleClinical case reports2023

HHV8 and EBV-negative primary effusion-based lymphoma: A case report of a new provisional entity and review of literature.

Marta Canelo-Vilaseca, Gustavo Tapia, Elisa Orna, Marc Sorigué, Isabel Granada, Azahara Palomar-Muñoz, Ana Castillo, Javier Grau, Alba Mesa, Josep-Maria Ribera and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marta Canelo-VilasecaHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.ORCID https://orcid.org/0000-0003-4479-4925
Gustavo TapiaPathology Department Hospital Germans Trias i Pujol Badalona Spain.
Elisa OrnaHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.
Marc SoriguéHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.
Isabel GranadaHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.
Azahara Palomar-MuñozNuclear Medicine-PET (IDI) Department University Hospital of Bellvitge-IDIBELL Barcelona Spain.
Ana CastilloPathology Department Hospital Germans Trias i Pujol Badalona Spain.
Javier GrauHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.
Alba MesaHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.
Josep-Maria RiberaHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.ORCID https://orcid.org/0000-0003-1042-6024
Juan-Manuel SanchoHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.ORCID https://orcid.org/0000-0001-7168-6538
José-Tomás NavarroHematology Department ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona Badalona Spain.ORCID https://orcid.org/0000-0001-9101-6013
Universitat Autònoma de Barcelona · ESHospital Universitari Germans Trias i Pujol · ESInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: HHV8- and EBV-negative primary effusion lymphoma is an extremely rare neoplasm involving body cavities without detectable tumor mass. It usually presents in elderly patients without known immunodeficiency. Compared to primary effusion lymphoma, it has a better prognosis. Primary effusion lymphoma (PEL) is a rare non-Hodgkin lymphoma confined exclusively to body cavities without detectable tumor masses. The term PEL-like is an entity similar to PEL in clinical presentation but without relation to human herpesvirus 8 (HHV8). We report a case of HHV8- and EBV-negative primary effusion-based lymphoma.

Indexed as

HHV8 and EBV‐negative primary effusion‐based lymphomaPELPEL‐like

Identifiers

PMID37180332
PMCPMC10167618
OpenAlexW4376641570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.